

The information contained within this announcement is deemed to constitute inside information as stipulated under the Market Abuse Regulation (EU) No. 596/2014, as incorporated into UK law by the European Union (Withdrawal) Act 2018. Upon the publication of this announcement, this inside information is now considered to be in the public domain.

3 June 2025



CRISM Therapeutics Corporation
("CRISM", "CRISM Therapeutics" or the "Company")

Establishment of Scientific Advisory Board

CRISM Therapeutics Corporation (AIM: CRTX) the innovative UK drug delivery company focused on the localised delivery of chemotherapy drugs, announces that it has established a Scientific Advisory Board ("SAB") to provide the Company with expert guidance as it prepares to submit its Clinical Trial Application ("CTA") authorisation for ChemoSeed in glioblastoma.

The role of the SAB is to provide the Company with specific guidance on its upcoming registration grade Phase II clinical trial for irinotecan ChemoSeed in patients with glioblastoma. Furthermore, the Company can benefit from the external perspectives which the members of the SAB can bring to steer its future strategies. Details of the SAB members are as follows:

Garth Cruickshank, PhD, MBBS, FRCS (Ed), FRCS (Eng), FRCS (SN)

Garth Cruickshank is Emeritus Professor of Neurosurgery at the University of Birmingham. He has worked on hypoxic mechanisms in brain tumour behaviour using per-operative oxygen electrodes and was the first neurosurgeon to inject modified live oncolytic HSV1716 into human brain tumours. He has participated in several interventional glioma clinical trials including HSVtk, and TGFbeta infusion. He helped develop the NICE Improving Outcomes Guidance (2006) for Brain Tumours and was the Lead Clinician for 2018 NICE Brain Tumour current clinical guidelines. He has acted as an advisor for care provider, BSI Healthcare and a reviewer for the National Institute for Health and Care Research.

Dr. Vinton Cheng MBBS MRCP PGDip DPhil

Dr. Vinton Cheng is an Associate Clinical Professor and Honorary Consultant in Medical Oncology at the University of Birmingham with a clinical focus on the holistic management of adult patients with primary and metastatic brain tumours, including with the delivery of systemic therapies. Dr Cheng's research interests are in developing systemic therapy trials for brain tumour patients and studying the progression of cancer in the brain.

Commenting on the establishment of the SAB, CRISM CEO Andrew Webb said: *We believe that CRISM has established a strong scientific advisory board, with both Vinton and Garth highly experienced in the field of neuro-oncology. They have significant expertise in the field of running successful clinical trials, regulation and academia and we are fortunate to be able to draw on this as the Company prepares its CTA authorisation and subsequent phase II clinical trial for ChemoSeed in glioblastoma.*

-Ends-

Enquiries:

Company
CRISM Therapeutics Corporation
Andrew Webb, CEO
Chris McConville, CSO
via Burson Buchanan

Nomad and Broker
S.P. Angel Corporate Finance LLP
Richard Morrison
Adam Cowl
+44 (0) 20 3470 0470

Financial PR
Burson Buchanan
Mark Court / Jamie Hooper
CRISM@buchanancomms.co.uk
+44 (0) 20 7466 5000

About CRISM Therapeutics Corporation

CRISM Therapeutics Corporation has developed an innovative drug delivery technology to improve the clinical performance of cancer treatments for solid tumours through the local delivery of chemotherapy drugs.

ChemoSeed, CRISM's lead product, can be implanted directly into the tumour or the resection margin following the removal of a tumour. This directs that therapeutic concentrations of chemotherapy drugs reach the deep-seated tumour tissue or cover the entire resection margin. In the case of treating glioblastoma, ChemoSeeds can be implanted during surgery thereby bypassing the blood brain barrier, which prevents other treatments from being able to reach the tumour and be effective.

CRISM is expects to submit a clinical trial application for ChemoSeed glioblastoma in H2 2025.

For more information please visit: <https://www.crismltherapeutics.com/>

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rs@seg.com or visit www.rs.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our [Privacy Policy](#).

END

MSCFTMRTMTJMBIA